Topical DNA aptamer therapeutics for the skin

Irmgard Förster and Günter Mayer, together with their respective collaborative teams, report in this issue on the development of the first-ever DNA aptamer-containing topical cream.¹ They successfully treated allergic contact dermatitis (ACD) in mice through DNA aptamer-mediated inhibition of the chemokine CCL22, which blocks the recruitment of T cells, thereby reducing inflammation associated with ACD. ACD is an inflammatory skin condition affecting 16.5% of the population,² caused by an immune response to specific allergens such as metals, fragrances, and preservatives found in common items such as cosmetics, jewelry, or cleaning products. Most allergic reactions originate from chemokine-mediated cell migration that recruits immune cells as a result of inflammation.³ Inhibition of immune cell recruitment is a key therapeutic target. The manuscript shows identification and application of a DNA aptamer to inhibit CCL22 from signaling immune cells to block ACD inflammation in mice. Being the first example of a therapeutic DNA aptamer topical cream, this publication is a pivotal moment in aptamer-based therapeutics and, more specifically, for ACD treatment.